[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cortex Neurovascular\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":85},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100641202","embrace-obs-single-site-observational-registry-of-patient-reported-outcomes-following-mma-embolization-for-migraine-100641202",false,"NCT07652034","EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine","Enduring Migraine Benefit From Responsive Artery Coil Embolization - Observational (EMBRACE-OBS): A Single-Site Registry of Patient-Reported Outcomes Following Routine Clinical Care for Migraine","EMBRACE-OBS","Inclusion Criteria:\n\n* Adults aged 18 to 64 years\n* Diagnosis of migraine\n* Have undergone or plan to undergo middle meningeal artery (MMA) embolization as part of routine clinical care, independent of study participation\n* Able and willing to provide informed consent\n* Able to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy at the time of enrollment\n* Inability to provide informed consent\n* Inability to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments\n* Insufficient clinical or patient-reported outcome data for the planned analyses","ALL","18 Years","64 Years",{"count":21,"type":22},50,"ESTIMATED","12 Months","OBSERVATIONAL","EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine who have undergone or plan to undergo middle meningeal artery (MMA) embolization. The study describes changes in headache frequency, headache severity, medication use, migraine-related disability, quality of life, and reported adverse events over time without influencing clinical care.",[27,28,29],"Migraine Disorders","Chronic Migraine Headache","Migraine",[31,32,29,33,34,35,36,37,15],"Middle Meningeal Artery Embolization","MMA Embolization","Headache","Patient-Reported Outcomes","HIT-6","Observational Registry","Neurointervention","NOT_YET_RECRUITING","2026-06-16",{"date":41,"type":42},"2026-06-18","ACTUAL",{"date":44,"type":22},"2026-07-01",{"date":46,"type":22},"2028-06-01",{"name":48,"class":49},"Cortex Neurovascular","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":50},"100617067","embrace-study-enduring-migraine-benefit-from-responsive-artery-coil-embolization-100617067","NCT07313800","EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization","Enduring Migraine Benefit From Responsive Artery Coil Embolization (EMBRACE): A Single-Site, Non-Significant Risk Pilot Study of Middle Meningeal Artery Embolization Using FDA-Cleared Coils for Refractory Episodic Migraine","EMBRACE","Inclusion Criteria:\n\n* Age 18-60 years\n* Diagnosis of migraine (with or without aura)\n\n  -≥8 headache days per month\n* Failure of ≥2 preventive medication classes\n* Ability to complete electronic headache diary and surveys\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Secondary headache disorders\n* Prior MMA embolization\n* Contraindication to angiography or embolization\n* Pregnancy\n* Inability to comply with follow-up","60 Years",{"count":61,"type":22},25,"INTERVENTIONAL",[64],"NA","This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).",[27,67,68],"Refractory Migraine","Chronic Migraine",[31,32,67,70,71,72,73,74,75,76],"Coil Embolization","Neurovascular Intervention","Migraine Prevention","TEMMA","TEMMA procedure","TEMMA protocol","Targeted Embolization for Migraine Management","2026-02-02",{"date":79,"type":42},"2026-02-04",{"date":81,"type":22},"2026-03-01",{"date":83,"type":22},"2028-03-01",{"name":48,"class":49},""]